The firm is anticipating approvals in 2026 to push Enhertu into earlier breast cancer indications and Datroway into ...

After the approval and rescinding of one company's designation, experts examine why sponsors might still leverage the program and what might give them pause.

Final data from the AZUR-1 trial is highly anticipated later this year after a collaborative study with MSK showed a 100 percent complete response rate for the PD-1 inhibitor.

Global sales of the anti-amyloid Alzheimer's drug, approved in 2023, grew 74 percent between Q1 2025 and 2026, reaching $168 ...

The agency is slated to decide whether to grant accelerated approval to the drug for treating NSCLC patients with EGFR exon 20 insertion mutations by February 2027.

After reviewing data from an early-phase trial on JANX008, the company said it will put its resources toward advancing other immunotherapies in its pipeline.

Animal model testing of the digenic gene therapy found it restored enzyme activity, improved growth, and prevented death.

Company execs lamented slow progress on pricing discussions with world leaders after inking a most-favored nation deal with ...

Profluent, which will design recombinases for the collaboration, could receive up to $2.25 billion in the deal.

The company recently initiated a rolling BLA submission to the FDA seeking approval for lonvo-z as a one-time treatment for ...

The biotech will look for tumor-specific antigens in Gustave Roussy patients, which will inform preclinical studies a colorectal and pancreatic cancer therapy.

"Epitopea's CryptiVax-1001 vaccine, which targets a novel repertoire of tumor-specific antigens, has the potential to meaningfully extend remission for patients with few effective treatment options," ...